BDR Pharma launches Nintenib (Nintedanib) to treat Idiopathic Pulmonary Fibrosis in India
BDR Pharmaceutical today announces the launch of 100mg and 150 mg Nintedanib under the brand name Nintenib for the treatment of Idiopathic Pulmonary Fibrosis (IPF)....